0.0050
0.0000
(0.00%)
At close: April 18 at 4:00:00 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Pierre Laurin B.Sc.Pharm., M.Sc. | Interim CEO & Chairman | -- | -- | 1961 |
| Mr. Luc Mainville M.B.A. | Senior VP & CFO | 135.04k | -- | 1964 |
| Mr. Guy-Paul Allard | VP of Legal Affairs & Corporate Secretary | -- | -- | -- |
| Dr. Jonathan Sackier | Senior Vice President of Medical Affairs | 202.19k | -- | -- |
| Mr. Frédéric Dumais | Director of Communications & Investor Relations | -- | -- | -- |
| Mr. Benedek Simo | Controller | -- | -- | -- |
ChitogenX Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. It develops Ortho-R, a biopolymer for rotator cuff repair; and Ortho-M, a biopolymer for meniscus repair. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.
Corporate Governance
ChitogenX Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 26, 2025 at 8:00 PM UTC - May 30, 2025 at 8:00 PM UTC
ChitogenX Inc. Earnings Date
Recent Events
Recent Events Information Not Available